icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TABRECTA (capmatinib).
Voir aussi
Décision d'accès précoce
05/08/2022
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
npz6Dr7uMHgeTubj